Status:
COMPLETED
Satraplatin for Patients With Metastatic Breast Cancer (MBC)
Lead Sponsor:
Agennix
Conditions:
Metastatic Breast Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
To determine the objective response rate (ORR) of oral satraplatin in patients with Metastatic Breast Cancer.
Detailed Description
This is a Phase II open label, nonrandomized study for patients with metastatic breast cancer. WHAT IS SATRAPLATIN: Satraplatin is a member of the platinum-based class of chemotherapy drugs. Platinu...
Eligibility Criteria
Inclusion
- Has cytologically or pathologically confirmed breast cancer that is metastatic
- Must have had prior HerceptinÒ therapy if patient has HER2+ (overexpressing) breast cancer. HER2 is considered overexpressed if it is 3+ by IHC or if the gene is amplified by Flourescence in situ hybridization (FISH)
- Has had no more than 1 prior chemotherapy regimen for MBC
- Has had no prior platinum-based therapy
- Has an ECOG Performance Status (PS) 0-2
Exclusion
Key Trial Info
Start Date :
November 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2008
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00265655
Start Date
November 1 2005
End Date
February 1 2008
Last Update
March 28 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
US Oncology
Dallas, Texas, United States, 75204